SPECIAL REPORT / Europe’s leading cardiologists have advised policymakers to look into unexpected areas such as e-cigarettes and personalised medicine in their efforts to prevent cardiovascular diseases.
High temperatures, heat waves and extreme temperature fluctuations pose an ever-increasing threat to the global population, with a recent study by the German Weather Service indicating higher health risks. EurActiv Germany reports .
French doctors prescribe more patented statins than their European counterparts. The country’s health service spends €1.2 billion on statins every year, double the budget of some European countries. EurActiv France reports .
Europe will face an obesity crisis of vast proportions by 2030, according to new World Health Organization projections, with many countries likely to see far more than half of adults above the healthy weight limit.
FH is an inherited condition associated with high “bad” cholesterol (low-density lipoprotein-cholesterol or LDL-C) and may predispose a person to premature cardiovascular disease (CVD). People with FH are unable to process the body’s natural supply of cholesterol, leading to very high levels of “bad” cholesterol that can block arteries and lead to a heart attack or stroke.
A recent report by the French Directorate for Research, Studies and the Evaluation of Statistics (DREES) has placed France ahead of its EU partners in terms of cardiovascular health, despite a relatively high rate of smoking among young people. EurActiv France reports .
American researchers believe that 97% of people over the age of 66 should regularly take statins to reduce their risk of heart disease. But there is still no consensus within the medical community on the benefits of the drugs. EurActiv France reports .
Heart disease is the leading cause of death in Europe, claiming about four million victims each year. Some regions are affected to a much greater extent than others, and disparities are clearly visible both on a national level and across the continent. EurActiv France reports.
A new generation of anticoagulants have been blamed for the deaths of patients in France. Studies from two leading French health agencies conclude that they do not pose a serious risk, but doubts remain. EurActiv France reports .